Nanolive hosts this event on “Non-invasive, high content live cell assays to increase translational relevance of in vitro drug development of biologics and small molecules”.
In this webinar, we present the following use-cases of our immuno-oncology and cytotoxicity assays from industry-leading biopharma companies to test toxicity, selectivity, uptake and expression of different targeted therapies.
- Immune cell therapeutics:
- Bispecific antibody screening in a T cell-target cell co-culture (Light Chain Bioscience)
- Drug selectivity and cytotoxicity:
- mRNA expression and cytotoxicity (TRON)
- Drug selectivity in co-cultures: senolytics (dsm-firmenich)
- Measuring particle uptake (bit.bio)
This webinar lasts 20 to 25 minutes.
Read our latest news
Webinar – CAR T cells live and up-close: Metabolic engineering for enhanced function
Nanolive hosted this event on "CAR T cells live and up-close: Metabolic engineering for enhanced function." In this webinar, presented by Dr Roddy O’Connor, Research Assistant Professor at University of Pennsylvania’s renowned Center for Cellular Immunotherapies and...
Newsletter November: The R&D cosmetics teams leading in vitro innovation
With animal-testing bans in place, cosmetics R&D urgently needs reliable in vitro models that combine predictive power, reproducibility, and ethical compliance. Nanolive’s CRO services provide label-free, high-content live-cell analysis to assess ingredient safety, toxicity, and efficacy…
Newsletter October: How can AI simplify cell painting?
Phenotypic screening has re-emerged as a powerful approach for identifying and characterizing drug candidates, especially in an era where mechanism-based screening often overlooks complex biological responses…